SCHEMBL492973

SCHEMBL492973

CN(C)C(c1cccc(F)c1)C1CCC(NC(=O)COCCN(C)S(=O)(=O)c2ccc(OC(F)(F)F)cc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.42
BDKRB1 P46663 1/20 0.41
OPRM1 P35372 1/20 0.41
DPP4 P27487 4/20 0.40
DPP7 Q9UHL4 4/20 0.40
OPRL1 P41146 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 1/20 0.36
FASN P49327 1/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
SPPL2B Q8TCT7 1/20 0.36
SPPL2A Q8TCT8 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
LMNA P02545 3/20 0.35
EPHX2 P34913 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL492686 0.92 ALDH1A1 (0.41) L3MBTL1BDKRB1OPRL1SMN1; SMN2LMNA
SCHEMBL492656 0.92 L3MBTL1 (0.44) L3MBTL1BDKRB1DPP4DPP7SMN1; SMN2
SCHEMBL493439 0.91 L3MBTL1 (0.44) L3MBTL1BDKRB1DPP4DPP7SMN1; SMN2
SCHEMBL493168 0.90 CXCR3 (0.41) BDKRB1OPRM1DPP4DPP7SMN1; SMN2
SCHEMBL493055 0.89 OPRL1 (0.39) OPRL1SMN1; SMN2PSEN1PSEN2APH1B
SCHEMBL492810 0.89 OPRM1 (0.41) L3MBTL1BDKRB1OPRM1DPP4DPP7
SCHEMBL492917 0.87 LMNA (0.47) OPRL1SMN1; SMN2LMNAGAAHTT
SCHEMBL492490 0.86 MAPT (0.39) L3MBTL1OPRL1SMN1; SMN2MAPTGAA
SCHEMBL493028 0.84 L3MBTL1 (0.42) L3MBTL1BDKRB1DPP4DPP7SMN1; SMN2
SCHEMBL492822 0.84 LMNA (0.40) SMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106055-B2 Substituted amide compounds GRUENENTHAL GMBH (DE) 2012-01-31 US claimed
US-20080306084-A1 Substituted Amide Compounds GRUENENTHAL GMBH (DE) 2008-12-11 US claimed
US-8106055-B2 Substituted amide compounds GRUENENTHAL GMBH (DE) 2012-01-31 US disclosed
EP-2139851-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-01-06 EP disclosed
US-20080306084-A1 Substituted Amide Compounds GRUENENTHAL GMBH (DE) 2008-12-11 US disclosed
WO-2008131946-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306084-A1 Substituted Amide Compounds OPRK1, NAA50, ACMSD L3MBTL1 4753/4885BDKRB1 1622/4885OPRM1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.